卵巢癌中胚系与体细胞同步测序:突变率及对临床决策的影响
该研究回顾性分析了43例卵巢癌患者同时进行血液与肿瘤DNA测序的结果,发现致病性胚系突变6例(14%)、可靶向体细胞突变15例(35%)。在40例有足够随访的病例中,85%的医生记录了遗传检测结果,30%的病例临床决策受到影响。结论认为同步测序可高效提供指导卵巢癌治疗的信息,识别体细胞BRCA突变以便在诊断时使用PARP抑制剂维持治疗。
要点
- 同步胚系与体细胞测序可识别卵巢癌诊断时的体细胞BRCA突变。
- 43例中致病性胚系突变6例(14%),可靶向体细胞突变15例(35%)。
- 40例有随访病例中,85%医生记录审阅结果,30%影响临床决策。
核心结论
- 同步胚系与肿瘤测序是指导卵巢癌患者护理的有效方式,可在诊断时识别体细胞BRCA突变,使医生能提供PARP抑制剂维持治疗并改善患者结局。
研究设计与样本
- 回顾性审查2017年7月至2018年7月在本机构接受BROCA检测同步测序配对血液和肿瘤组织DNA的卵巢癌病例医疗记录。
主要发现
- 共识别43名女性(36例新诊断,7例复发),诊断时平均年龄60岁。
- 肿瘤样本来源:手术标本31例(72.1%),活检11例(25.6%),细胞学1例(2.3%)。
- 致病性胚系突变6例(14%),可靶向体细胞突变15例(35%),同时有体细胞和胚系突变1例(2%)。
- BRCA突变占所有突变的59%。
- 40例有足够随访的病例中,34例(85%)医生记录审阅了遗传检测结果,12例(30%)影响了临床决策。
临床怎么用
- 对卵巢癌患者可考虑同步胚系和肿瘤测序,以识别体细胞BRCA突变,从而指导PARP抑制剂维持治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Germline and somatic BRCA1 and BRCA2 (BRCA) mutations predict treatment response in patients with epithelial ovarian, peritoneal or fallopian tube cancer (OC), yet only germline testing is routinely pursued or reimbursed at diagnosis. We report our experience with clinical testing of paired tumor and germline DNA for OC mutations. METHODS: Simultaneous sequencing using the BROCA assay of DNA from paired blood and neoplastic tissue became clinically available at our institution in 2017. We retrospectively reviewed the medical records of OC cases tested from 7/2017 to 7/2018. We calculated the rates of known pathogenic germline mutations and actionable somatic mutations, defined as those for which targeted therapies exist. RESULTS: We identified 43 women (36 new diagnoses, seven recurrences) who underwent testing. Average age at diagnosis was 60. OC samples came from surgical specimens in 31 cases (72.1%), from biopsy in 11 cases (25.6%), and from cytology in one case (2.3%). We identified pathogenic germline mutations in six cases (14%), actionable somatic mutations in 15 cases (35%), and both a somatic and germline mutation in one case (2%). BRCA mutations accounted for 59% of all mutations. Of 40 cases with sufficient follow-up, providers documented reviewing results of genetic testing in 34 (85%), which influenced clinical decisions in 12 (30%). CONCLUSIONS: Simultaneous germline and tumor sequencing is an efficient way to provide enhanced information to guide the care of OC patients. This approach can identify somatic BRCA mutations at diagnosis, allowing physicians to provide PARP inhibitor maintenance and improve outcomes for those patients.
引用
- Jorge S, McFaddin AS, Doll KM, et al. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. Gynecol Oncol. 2019. PMID: 31883735. doi:10.1016/j.ygyno.2019.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。